


## Fosamprenavir

<b>Cat. No.:</b>	HY-78726		
<b>CAS No.:</b>	226700-79-4		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>36</sub> N <sub>3</sub> O <sub>9</sub> PS		
<b>Molecular Weight:</b>	585.61		
<b>Target:</b>	HIV		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (170.76 mM)  
 \* "≥" means soluble, but saturation unknown.

	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.7076 mL	8.5381 mL	17.0762 mL
	5 mM	0.3415 mL	1.7076 mL	3.4152 mL
	10 mM	0.1708 mL	0.8538 mL	1.7076 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.5 mg/mL (4.27 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Fosamprenavir (Amprenavir phosphate;GW 433908) is a phosphate ester prodrug of the antiretroviral protease inhibitor Amprenavir, with improved solubility<sup>[1]</sup>. Anti-HIV infection<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

HIV<sup>[1]</sup>

## CUSTOMER VALIDATION

- Nat Commun. 2020 Sep 4;11(1):4417.
- Antimicrob Agents Chemother. 2020 Aug 20;64(9):e00872-20.
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

[1]. Falcoz C, et al. Pharmacokinetics of GW433908, a prodrug of amprenavir, in healthy male volunteers. J Clin Pharmacol. 2002 Aug;42(8):887-98.

**Caution: Product has not been fully validated for medical applications. For research use only.**